Robert W. Baird Issues Positive Forecast for Cencora (NYSE:COR) Stock Price

Cencora (NYSE:COR) had its price objective hoisted by Robert W. Baird from $355.00 to $395.00 in a research note released on Thursday morning,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

COR has been the subject of several other research reports. UBS Group boosted their price objective on Cencora from $350.00 to $380.00 and gave the company a “buy” rating in a report on Monday, October 27th. Morgan Stanley set a $330.00 price target on shares of Cencora and gave the company an “equal weight” rating in a research note on Wednesday, July 16th. Evercore ISI set a $340.00 price objective on shares of Cencora in a report on Wednesday, October 8th. Wall Street Zen cut shares of Cencora from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Cencora in a research report on Thursday, October 30th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $348.00.

Cencora Price Performance

Shares of NYSE COR opened at $360.29 on Thursday. The firm has a market capitalization of $69.85 billion, a P/E ratio of 37.07, a P/E/G ratio of 1.56 and a beta of 0.63. The firm’s 50-day moving average price is $312.89 and its 200-day moving average price is $298.79. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64. Cencora has a 1-year low of $223.92 and a 1-year high of $362.00.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. During the same period last year, the business posted $3.34 EPS. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Equities research analysts anticipate that Cencora will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 14th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, November 14th. This is an increase from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s payout ratio is 22.63%.

Insider Activity

In other Cencora news, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the sale, the chairman owned 305,913 shares in the company, valued at approximately $88,671,942.18. This trade represents a 9.30% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the transaction, the chief executive officer owned 37,940 shares in the company, valued at $12,398,792. The trade was a 11.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 41,544 shares of company stock valued at $12,230,941. Company insiders own 10.80% of the company’s stock.

Institutional Trading of Cencora

Several hedge funds have recently added to or reduced their stakes in COR. Cidel Asset Management Inc. grew its position in shares of Cencora by 7.0% during the 3rd quarter. Cidel Asset Management Inc. now owns 930 shares of the company’s stock valued at $291,000 after acquiring an additional 61 shares during the period. CENTRAL TRUST Co lifted its stake in Cencora by 116.0% in the third quarter. CENTRAL TRUST Co now owns 3,500 shares of the company’s stock valued at $1,094,000 after purchasing an additional 1,880 shares during the last quarter. Rothschild Capital Partners LLC purchased a new stake in Cencora in the third quarter worth $200,000. Longbow Finance SA bought a new stake in shares of Cencora in the third quarter valued at $10,553,000. Finally, Metis Global Partners LLC lifted its position in shares of Cencora by 7.7% during the 3rd quarter. Metis Global Partners LLC now owns 9,208 shares of the company’s stock valued at $2,878,000 after buying an additional 661 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.